Researchers dig into data: can Ultra-High HER2 levels predict Cancer's return?
NCT ID NCT07376174
Summary
This study looks back at the medical records of 300 people with early-stage, HER2-positive breast cancer who received a standard two-drug targeted therapy. Researchers want to understand if having extremely high levels of the HER2 protein is linked to a higher chance of the cancer coming back. The goal is to gather knowledge that could help doctors better predict patient outcomes in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medical Oncology
RECRUITINGJinan, Shandong, China
Conditions
Explore the condition pages connected to this study.